Drug launch readiness in less than 5 seconds.
You're 6 months out from a launch. You need to know what tier plans will put you on, which specialty pharmacies will dispense you, what the price-negotiation timeline looks like for your class, and where competitors sit on reimbursement. Type a drug name. Get the full picture in one call.
Every figure on this page comes from a single Medistill query that pulls together regulatory, pricing, coverage, channel, safety, and pipeline intelligence, joined and normalized so it reads in one frame.
ZANUBRUTINIB
- FDA approval
- 2019
- ATC
- L01EL03
- Max phase
- 4
- RxCUI
- 2262435
- UNII
- AG9MHG098Z
Authorization status & exclusivity runway
137 listed patents, max expiry 2034-04-22 (2034). EU regulatory: Authorised — sponsor BeOne Medicines Ireland Limited. Global essential-medicines status: On EML for 3 indication(s)
What it costs payers today
Prescribing spend 2023: $801M (+164% YoY). Not in any announced federal price-negotiation round.
Plans covering the drug, quarter by quarter
ZANUBRUTINIB first appeared in plan coverage in 2020Q2 at 4,599 plans. Peaked at 5,707. Current: 5,084 plans.
Pharmacy-benefit only
No medical-benefit reimbursement footprint. This drug is oral / self-administered and bills exclusively through the pharmacy benefit.
Specialty pharmacy network
12 payer / PBM sources list it as limited-distribution across 6 distinct dispensing pharmacies. Top: Onco360, Biologics by McKesson, CVS Caremark.
Who actually writes the script
1,963 visible prescribers writing $812M of prescribing spend. Top-10 = 4.2% of spend. Diffuse community-oncology prescriber base.
| Top 5 prescribers | Location | Drug cost | Claims |
|---|---|---|---|
| Leslie Rudolph | New York, NY | $6M | 494 |
| Jorge Castillo | Boston, MA | $4M | 318 |
| Leslie Rudolph | New York, NY | $4M | 306 |
| Jennifer Greenfield | Chicago, IL | $3M | 238 |
| Shayna Sarosiek | Boston, MA | $3M | 233 |
Adverse-event signal, cumulative
1,040 reports with outcome data. Shortage events last 24 months: 0.
Active recruiting trials
100 trials actively recruiting, including 8 in Phase 3.
- NCT07377578A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cel
- NCT07277231A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib
- NCT07321652Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated C
- NCT06742996A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib
- NCT06522555The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lympho
This brief is one call. Here's the rest.
Everything above comes from a single tool. A free account opens the rest of the same data so you can work a whole portfolio, not one drug at a time.
Batch your whole class or portfolio
The public scanner stops at one drug. With an account, run the entire BTK class, your launch portfolio, or a competitor's book in a single query and get every brief back side by side.
Pull the full prescriber roster
This page shows the top 5 prescribers. The account surfaces every visible prescriber with spend, claim counts, and location, so your field team can build a real targeting list.
Set watch-list alerts
Get notified when a drug's distribution network expands, when it's flagged for price negotiation, or when payer coverage shifts, instead of re-running the brief by hand.
Track competitors quarter over quarter
Trend coverage tier, plan count, and spend across the whole class over time to see who is gaining or losing access before it shows up in scripts.
Ask in plain language. Get a joined answer.
Connect Medistill to Claude and type a question. These are the kind of cross-dataset answers that normally take a week and three vendors.
Query
“Rank the top 50 prescribers of Brukinsa by prescribing spend, cross-referenced with the industry payments they took from competitors and any active trials they're running.”
Joins prescribing, industry-payment, and 577K clinical-trial records to build a targeting and conflict map no single tool produces.
Query
“Compare the full adverse-event profiles of every drug in the BTK class. Show total reports, serious-outcome rates, and the top reactions for each.”
Reads 25M+ post-marketing safety reports to put your signal in head-to-head class context.
Query
“Show negotiated commercial rates and plan market share for this drug's therapeutic area, broken out by state.”
Joins payer rate and enrollment data so access strategy is grounded in what payers actually pay.
Query
“Which specialty pharmacies dispense this drug, and how has the distribution network changed since launch?”
Tracks the distribution network across 1.12M coverage mappings and payer source documents over time.
Beyond pharma
The same account covers provider compliance screening across 150+ enforcement sources, a legal corpus of 10M+ court opinions for med-mal and litigation work, and full provider intelligence across 9.4M clinicians. Teams that wear more than one hat run all of it from one connection.
Run this on your own watch list
The public scanner above is rate-limited and stops at one drug per query. With a free Medistill account you get the full MCP surface: every drug, batch queries, your own watch lists, alerts when distribution networks expand or price-negotiation selections change, and 200+ other tools across payer, provider, regulatory, and compliance data.
Drug Launch Scanner questions
What the scanner profiles, which drugs it covers, and how it spans both the medical and pharmacy benefit.
What is the Drug Launch Scanner?
It is a free tool that profiles any FDA-approved drug across both how it is reimbursed and how it is covered, in one view. Type a brand or generic name and you get the regulatory status, spend and pricing, plan coverage over time, distribution channel, post-marketing safety signal, and active pipeline trials in a single brief.
What data does the Drug Launch Scanner pull together?
Each brief joins regulatory, pricing, coverage, channel, safety, and pipeline intelligence into one frame: FDA approval and exclusivity, EU regulatory status, patent expiry, spend and beneficiary counts, quarter-by-quarter plan coverage, distribution networks, reimbursement footprint where applicable, post-marketing adverse-event reporting, price-negotiation timeline for the class, and active recruiting clinical trials. It is derived intelligence, normalized and joined so it reads as one picture.
Which drugs can I look up?
Any approved drug by brand or generic name. The search box has autocomplete over a curated list of common brands across oncology, immunology, cardiometabolic, neurology, rare disease, and biosimilars, and it still accepts free text for anything not in that list.
Does it cover both the medical and pharmacy benefit?
Yes. Most launch tools look at only one side. The scanner reports pharmacy-benefit coverage and medical-benefit reimbursement together, so you can see where a drug bills and how plans treat it on each side.
What does launch readiness mean for a drug?
For a market access team, launch readiness is knowing before launch what tier plans will assign, which specialty pharmacies will dispense the product, where competitors sit on reimbursement, and what the price-negotiation timeline looks like for the class. The scanner answers those questions for any drug in one call.
Is the Drug Launch Scanner free, and how current is the data?
The public scanner is free and rate-limited to one drug per query. Data is refreshed on a rolling basis. A free Medistill account unlocks the full surface: every drug, batch queries, watch lists, and alerts when distribution networks expand or price-negotiation selections change.